AbbVie (ABBV)
(Delayed Data from NYSE)
$161.72 USD
-0.92 (-0.57%)
Updated May 1, 2024 04:00 PM ET
After-Market: $161.81 +0.09 (0.06%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ABBV 161.72 -0.92(-0.57%)
Will ABBV be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ABBV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABBV
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
ABBV: What are Zacks experts saying now?
Zacks Private Portfolio Services
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Is WisdomTree U.S. Quality Dividend Growth ETF (DGRW) a Strong ETF Right Now?
AbbVie (ABBV) Could Be a Great Choice
Other News for ABBV
Novartis Is Tracking Well Above the Industry
BeiGene, AbbVie patent spat to get trial from USPTO appeals board
US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
7 Safe Haven Stocks That Can Withstand the Market’s Worst Meltdowns
Novo, Teva, AstraZeneca issued FTC warnings over ‘bogus’ patents